09:25 AM EST, 02/27/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) reported Q4 core adjusted net income Thursday of $1.27 per diluted share, up from $1.05 a year earlier.

Analysts polled by FactSet expected $1.19.

Total revenue for the quarter ended Dec. 31 was $42.8 million, up from $28.1 million a year earlier.

Analysts surveyed by FactSet expected $39 million.

The company expects full year 2025 adjusted earnings in a range of $6.00 to $6.25 per diluted share on total revenue of $180 million to $200 million. Analysts polled by FactSet expect adjusted earnings of $6.07 per diluted share on total revenue of $187.1 million.